PRMT5 and Friedreich ataxia: Our studies indicate that a dysregulated PRMT5 in FA HSPCs plays an important role in suppressing p53-dependent tumor surveillance and suggest that PRMT5 may be a putative therapeutic target in FA tumorigenesis.